Product Description
Mechanisms of Action: CGRP Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Migraine Disorders|Coronary Artery Disease|Peripheral Vascular Diseases|Cerebrovascular Disorders|Ischemic Attack, Transient|Peripheral Arterial Disease|Ischemic Stroke
Phase 2: Migraine Disorders
Phase 1: Angina, Stable|Migraine Disorders|Coronary Artery Disease|Angina Pectoris|Myocardial Ischemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MK-0974-067 | P1 |
Completed |
Migraine Disorders |
2011-07-26 |
|
MK0974-065 | P3 |
Completed |
Migraine Disorders |
2011-04-08 |
|
MK-0974-065 | P3 |
Completed |
Migraine Disorders |
2011-04-08 |
|
MK-0974-034 | P3 |
Completed |
Ischemic Attack, Transient|Peripheral Vascular Diseases|Migraine Disorders|Cerebrovascular Disorders|Peripheral Arterial Disease|Ischemic Stroke |
2009-09-02 |